Andrikovics, Hajnalka <br/><br/>
First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.  [electronic resource] 

 -  Hematological oncology  Sep 2007 
 - 143-7 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0278-0232 
<br/><br/><label>Standard No.: </label>10.1002/hon.822  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--therapeutic use<br/>Benzamides<br/>Chromosome Breakage<br/>Female<br/>Fusion Proteins, bcr-abl--metabolism<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Piperazines--therapeutic use<br/>Pyrimidines--therapeutic use